Skip to content
Home
Charles E. Sparks, M.D.

Charles E. Sparks, M.D.

About Me

With a broad base of experience in clinical chemistry, Dr. Sparks serves as Director of the Protein Laboratory, and Associate Director of the Automated Laboratory. His primary research interest is in lipoproteins as a risk factor in the development of cardiovascular disease.
With a broad base of experience in clinical chemistry, Dr. Sparks serves as Director of the Protein Laboratory, and Associate Director of the Automated Laboratory. His primary research interest is in lipoproteins as a risk factor in the development of cardiovascular disease.

Faculty Appointments

Professor Emeritus - Department of Pathology and Laboratory Medicine (SMD)

Credentials

Post-doctoral Training & Residency

Fellow, Biochemistry
Medical College of Pennsylvania 1976 - 1977

Fellow, Cardiopulmonary Medicine
University of Pennsylvania 1975 - 1976

Resident
Hospital of the University of
Pennsylvania (Clinical Pathology) 1972 - 1975

Intern
New York Hospital, Cornell (Medicine)
Naval Hospital, St. Albans (Rotating) 1968 - 1969

Education

MD | Jefferson Medical College. Medicine. 1968

BS | Mass Inst Technology. Biochemistry. 1963

Awards

Secretarial Appointee. Department of Veterans Affairs Medical Research Service Merit Review Subcommittee for Endocrinology (Chair: Endocrinology-A Review Board, Fall 2003, Spring & Fall 2004) 2002 - 2005

Co-Chair. Thrombogenic Factors and Recurrent Coronary Events Symposium, Perugia, Italy 1998

Co-Chair. National Symposium Meeting, American Diabetes Association, Lipoproteins, Diabetes and Atherosclerosis. 1988

Invited Speaker. Gordon Research Conference on Atherosclerosis: "Is intestinal apo B a determinant for lipoprotein recognition?" 1981

Conferee. Lipid Metabolism and Atherosclerosis, 1978, '79, '80, '81, '84, '86, '88, '90, '92, '96, '00, '04 Gordon Research Conference, Kimball Union Academy, Meriden, NH 1978 - 2004

Individual Research Service Award Grantee, National Institutes of Health 1975 - 1977

Chief Resident in Pathology, University of Pennsylvania 1974 - 1975

Research

Apo B exists as B48 and B100 produced through a novel posttranscriptive mechanism of apo B mRNA editing producing protein products of differing size with differing metabolisms. The goal of our research is to understand apo B triglyceride-rich lipoprotein (TRL) assembly contrasting B100 and B48 synth...
Apo B exists as B48 and B100 produced through a novel posttranscriptive mechanism of apo B mRNA editing producing protein products of differing size with differing metabolisms. The goal of our research is to understand apo B triglyceride-rich lipoprotein (TRL) assembly contrasting B100 and B48 synthetic pathways. McArdle RH-7777 cells (McA) have provided many useful insights into inherent differences in B100 and B48 in TRL biogenesis. Recent studies indicate that B100-TRL assembly occurs by lipidation of conformationally "acceptable" B100. B48 undergoes initial lipidation similar to B100 followed by neutral lipidation of the precursor high density lipoprotein particle (B48-HDL) to form B48-TRL. More than 70% of the triglyceride (TG) fatty acids (FA) arise from cytosolic, stored TG through a process involving lipolysis/reesterification. Lipolyzed FAs, possibly through acylation reactions with PL intermediates, traverse the ER membrane by unknown means prior to fusion with B48-HDL. Unlike B100, that is synthesized and rapidly secreted by rat hepatocytes (RH), there is a kinetically distinct pool of B48 that has a long cellular retention time. We hypothesize that this pool may provide a ready supply of B48-HDL as a precursor for the rapid assembly of TRL via a later assembly step. In cells that make predominantly B48, such as intestine, the cellular pool of B48 allows TRL secretion to occur without a requirement for de novo apo B synthesis. We recently identified a novel protein factor, an apo B secretion enhancer (BSE), whose expression correlates with apo B mRNA abundance in McA cells transfected with BSE. Apo B mRNA abundance, however, does not correspond with a proportional increase in apo B secretion. Studies explore the role of BSE in the observed changes in apo B mRNA stability/transcription. Apo B degradation studies address the non-proportional secretory rate. A phospholipid (PL)-dependent pathway for the stimulation of apo B secretion by BSE is suggested as BSE is homologous with betaine homocysteine methyltransferase (BHMT), a methylation enzyme. An hypothesis explored is that, apart from its ability to stabilize apo B mRNA, an ER form of BSE may provide newly synthesized phosphatidylcholine (PC) via phosphatidylethanolamine (PE) methylation of phosphatidylserine (PS) and increased supply of PL may be a mechanism for the enhancing secretion of apo B.

Importance of the research is related to the role of apo B in lipid transport and as a factor associated with risk of arterial disease. Additional research focuses on the role of apo B as a risk factor in developing heart attacks, strokes, and in recurrent heart attacks in human populations.

Patents

Particle Stabilized Epitopes for Standardization

Issue date: June 16, 1997

Patent #: 171813

Country: Denmark

Inventors: Charles E Sparks, Janet D Sparks, Michael Violante

Particle Stabilized Epitopes for Standardization and Control of Immunoassays

Issue date: April 27, 1993

Patent #: 5,206,086

Country: United States

Inventors: Charles E Sparks, Janet D Sparks, Michael Violante

Particle Stabilized Epitopes for Standardization and Control of Immunoassays

Issue date: June 16, 1997

Patent #: 0312173

Country: Europe

Inventors: Charles E Sparks, Janet D Sparks, Michael Violante

Particle-Stabilized Epitopes for Standardization and Control of Immunoassays

Issue date: November 24, 1998

Patent #: 1,340,139

Country: Canada

Inventors: Charles E Sparks, Janet D Sparks, Michael Violante

Identifying Risk of a Medical Event

Issue date: March 17, 2015

Patent #: 8,979,753

Country: United States

Inventors: James P Corsetti, Arthur J Moss, Daniel H Ryan, Charles E Sparks

Publications

Journal Articles

Apolipoprotein B attenuates albuminuria-associated cardiovascular disease in prevention of renal and vascular endstage disease (PREVEND) participants.

Corsetti JP, Gansevoort RT, Bakker SJ, Sparks CE, Vart P, Dullaart RP

Journal of the American Society of Nephrology : JASN.. 2014 December 25 (12):2906-15. Epub 05/22/2014.

High-density lipoproteins: taking the good with the bad.

Sparks CE, Corsetti JP, Sparks JD

Current opinion in lipidology.. 2014 June 25 (3):230-2. Epub 1900 01 01.

Hepatic postprandial transition and very low-density lipoprotein biogenesis.

Sparks CE, Sparks JD

Current opinion in lipidology.. 2013 October 24 (5):450-2. Epub 1900 01 01.

Plasminogen activator inhibitor-2 polymorphism associates with recurrent coronary event risk in patients with high HDL and C-reactive protein levels.

Corsetti JP, Salzman P, Ryan D, Moss AJ, Zareba W, Sparks CE

PloS one.. 2013 8 (7):e68920. Epub 07/09/2013.

Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia.

Sparks JD, Sparks CE, Adeli K

Arteriosclerosis, thrombosis, and vascular biology.. 2012 September 32 (9):2104-12. Epub 07/12/2012.

Hepatic steatosis and VLDL hypersecretion.

Sparks CE, Sparks JD

Current opinion in lipidology.. 2012 August 23 (4):395-7. Epub 1900 01 01.

Apolipoprotein E predicts incident cardiovascular disease risk in women but not in men with concurrently high levels of high-density lipoprotein cholesterol and C-reactive protein.

Corsetti JP, Gansevoort RT, Bakker SJ, Navis G, Sparks CE, Dullaart RP

Metabolism: clinical and experimental.. 2012 July 61 (7):996-1002. Epub 01/05/2012.

Acute suppression of apo B secretion by insulin occurs independently of MTP.

Sparks JD, Chamberlain J, O'Dell C, Khatun I, Hussain MM, Sparks CE

Biochemical and biophysical research communications.. 2011 March 11406 (2):252-6. Epub 02/18/2011.

Interleukin-6 mediates hepatic hypersecretion of apolipoprotein B.

Sparks JD, Cianci J, Jokinen J, Chen LS, Sparks CE

American journal of physiology. Gastrointestinal and liver physiology.. 2010 October 299 (4):G980-9. Epub 07/22/2010.

Cholesteryl ester transfer protein polymorphism (TaqIB) associates with risk in postinfarction patients with high C-reactive protein and high-density lipoprotein cholesterol levels.

Corsetti JP, Ryan D, Rainwater DL, Moss AJ, Zareba W, Sparks CE

Arteriosclerosis, thrombosis, and vascular biology.. 2010 August 30 (8):1657-64. Epub 05/20/2010.

Inflammation reduces HDL protection against primary cardiac risk.

Corsetti JP, Gansevoort RT, Sparks CE, Dullaart RP

European journal of clinical investigation.. 2010 June 40 (6):483-9. Epub 04/14/2010.

Lipid metabolism: insights into the complexity of VLDL metabolic pathways.

Sparks CE, Sparks JD

Current opinion in lipidology.. 2010 June 21 (3):280-1. Epub 1900 01 01.

Lp(a) and risk of recurrent cardiac events in obese postinfarction patients.

Corsetti JP, Ryan D, Rainwater DL, Moss AJ, Zareba W, Block RC, Sparks CE

Obesity.. 2008 December 16 (12):2717-22. Epub 10/16/2008.

Overindulgence and metabolic syndrome: is FoxO1 a missing link?

Sparks JD, Sparks CE

The Journal of clinical investigation.. 2008 June 118 (6):2012-5. Epub 1900 01 01.

Plasminogen activator inhibitor-1 polymorphism (4G/5G) predicts recurrence in nonhyperlipidemic postinfarction patients.

Corsetti JP, Ryan D, Moss AJ, Rainwater DL, Zareba W, Sparks CE

Arteriosclerosis, thrombosis, and vascular biology.. 2008 March 28 (3):548-54. Epub 12/20/2007.

NAD(P)H oxidase polymorphism (C242T) and high HDL cholesterol associate with recurrent coronary events in postinfarction patients.

Corsetti JP, Ryan D, Moss AJ, Zareba W, Sparks CE

Atherosclerosis.. 2008 January 196 (1):461-468. Epub 01/09/2007.

Plasminogen activator inhibitor-1 polymorphism (4G/5G) predicts recurrence in nonhyperlipidemic postinfarction patients

Corsetti, J.P.; Ryan, D.; Moss, A.J.; Rainwater, D.L.; Zareba, W.; Sparks, C.E.;.

Arterioscler Thromb Vasc Biol. 2008; 28(3): 548-54.

Overindulgence and metabolic syndrome: is FoxO1 a missing link?

Sparks, J.D.; Sparks, C.E.;.

J Clin Invest. 2008; 118(6): 2012-5.

Glycoprotein Ibalpha polymorphism T145M, elevated lipoprotein-associated phospholipase A2, and hypertriglyceridemia predict risk for recurrent coronary events in diabetic postinfarction patients.

Corsetti JP, Ryan D, Moss AJ, Rainwater DL, Zareba W, Sparks CE

Diabetes.. 2007 May 56 (5):1429-35. Epub 02/15/2007.

PI3-kinase activity modulates apo B available for hepatic VLDL production in apobec-1-/- mice.

Chirieac DV, Davidson NO, Sparks CE, Sparks JD

American journal of physiology. Gastrointestinal and liver physiology.. 2006 September 291 (3):G382-8. Epub 06/22/2006.

Elevated HDL is a risk factor for recurrent coronary events in a subgroup of non-diabetic postinfarction patients with hypercholesterolemia and inflammation.

Corsetti JP, Zareba W, Moss AJ, Rainwater DL, Sparks CE

Atherosclerosis.. 2006 July 187 (1):191-7. Epub 10/20/2005.

High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients.

Corsetti JP, Rainwater DL, Moss AJ, Zareba W, Sparks CE

Clinical chemistry.. 2006 July 52 (7):1331-8. Epub 05/18/2006.

Hepatic very-low-density lipoprotein and apolipoprotein B production are increased following in vivo induction of betaine-homocysteine S-methyltransferase.

Sparks JD, Collins HL, Chirieac DV, Cianci J, Jokinen J, Sowden MP, Galloway CA, Sparks CE

The Biochemical journal.. 2006 April 15395 (2):363-71. Epub 1900 01 01.

Serum glucose and triglyceride determine high-risk subgroups in non-diabetic postinfarction patients.

Corsetti JP, Zareba W, Moss AJ, Sparks CE

Atherosclerosis.. 2005 December 183 (2):293-300. Epub 05/31/2005.

Atherosclerotic risk genotypes and recurrent coronary events after myocardial infarction.

Moss AJ, Ryan D, Oakes D, Goldstein RE, Greenberg H, Bodenheimer MM, Brown MW, Case RB, Dwyer EM, Eberly SW, Francis CW, Gillespie JA, Krone RJ, Lichstein E, MacCluer JW, Marcus FI, McCarthy J, Sparks CE, Zareba W

The American journal of cardiology.. 2005 July 1596 (2):177-82. Epub 1900 01 01.

Apolipoprotein B determines risk for recurrent coronary events in postinfarction patients with metabolic syndrome.

Corsetti JP, Zareba W, Moss AJ, Sparks CE

Atherosclerosis.. 2004 December 177 (2):367-73. Epub 1900 01 01.

Altered triglyceride-rich lipoprotein production in Zucker diabetic fatty rats.

Chirieac DV, Collins HL, Cianci J, Sparks JD, Sparks CE

American journal of physiology. Endocrinology and metabolism.. 2004 July 287 (1):E42-9. Epub 02/17/2004.

Metabolic syndrome best defines the multivariate distribution of blood variables in postinfarction patients.

Corsetti JP, Zareba W, Moss AJ, Ridker PM, Marder VJ, Rainwater DL, Sparks CE

Atherosclerosis.. 2003 December 171 (2):351-8. Epub 1900 01 01.

History of hypertension and enhanced thrombogenic activity in postinfarction patients.

Fadl YY, Zareba W, Moss AJ, Marder VJ, Sparks CS, Miller Watelet LF, Carroll ER

Hypertension.. 2003 April 41 (4):943-9. Epub 03/10/2003.

Insulin suppression of VLDL apo B secretion is not mediated by the LDL receptor.

Chirieac DV, Cianci J, Collins HL, Sparks JD, Sparks CE

Biochemical and biophysical research communications.. 2002 September 13297 (1):134-7. Epub 1900 01 01.

Association of C-reactive protein and serum amyloid A with recurrent coronary events in stable patients after healing of acute myocardial infarction.

Harb TS, Zareba W, Moss AJ, Ridker PM, Marder VJ, Rifai N, Miller Watelet LF, Arora R, Brown MW, Case RB, Dwyer EM, Gillespie JA, Goldstein RE, Greenberg H, Hochman J, Krone RJ, Liang CS, Lichstein E, Little W, Marcus FI, Oakes D, Sparks CE, VanVoorhees L,

The American journal of cardiology.. 2002 January 1589 (2):216-21. Epub 1900 01 01.

Increased level of von Willebrand factor is significantly and independently associated with diabetes in postinfarction patients. THROMBO Investigators.

Zareba W, Pancio G, Moss AJ, Kalaria VG, Marder VJ, Weiss HJ, Watelet LF, Sparks CE

Thrombosis and haemostasis.. 2001 September 86 (3):791-9. Epub 1900 01 01.

Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apoB production.

Chirieac DV, Chirieac LR, Corsetti JP, Cianci J, Sparks CE, Sparks JD

American journal of physiology. Endocrinology and metabolism.. 2000 November 279 (5):E1003-11. Epub 1900 01 01.

Insulin-treated Zucker diabetic fatty rats retain the hypertriglyceridemia associated with obesity.

Sparks JD, Shaw WN, Corsetti JP, Bolognino M, Pesek JF, Sparks CE

Metabolism: clinical and experimental.. 2000 November 49 (11):1424-30. Epub 1900 01 01.

Effect of smoking on lipid and thrombogenic factors two months after acute myocardial infarction.

Fisher SD, Zareba W, Moss AJ, Marder VJ, Sparks CE, Hochman J, Liang C, Krone RJ,

The American journal of cardiology.. 2000 October 1586 (8):813-8. Epub 1900 01 01.

B48 is preferentially translated over B100 in cells with increased endogenous apo B mRNA.

Collins HL, Sparks CE, Sparks JD

Biochemical and biophysical research communications.. 2000 July 14273 (3):1156-60. Epub 1900 01 01.

Gender-related differences in thrombogenic factors predicting recurrent cardiac events in patients after acute myocardial infarction. The THROMBO Investigators.

Kalaria VG, Zareba W, Moss AJ, Pancio G, Marder VJ, Morrissey JH, Weiss HJ, Sparks CE, Greenberg H, Dwyer E, Goldstein R, Watelet LF

The American journal of cardiology.. 2000 June 1585 (12):1401-8. Epub 1900 01 01.

Effect of dietary fat on the development of non-insulin dependent diabetes mellitus in obese Zucker diabetic fatty male and female rats.

Corsetti JP, Sparks JD, Peterson RG, Smith RL, Sparks CE

Atherosclerosis.. 2000 February 148 (2):231-41. Epub 1900 01 01.

Apolipoprotein B mRNA and lipoprotein secretion are increased in McArdle RH-7777 cells by expression of betaine-homocysteine S-methyltransferase.

Sowden MP, Collins HL, Smith HC, Garrow TA, Sparks JD, Sparks CE

The Biochemical journal.. 1999 August 1341 ( Pt 3) (Pt 3):639-45. Epub 1900 01 01.

Thrombogenic factors and recurrent coronary events.

Moss AJ, Goldstein RE, Marder VJ, Sparks CE, Oakes D, Greenberg H, Weiss HJ, Zareba W, Brown MW, Liang CS, Lichstein E, Little WC, Gillespie JA, Van Voorhees L, Krone RJ, Bodenheimer MM, Hochman J, Dwyer EM, Arora R, Marcus FI, Watelet LF, Case RB

Circulation.. 1999 May 1899 (19):2517-22. Epub 1900 01 01.

Ethanol increases apolipoprotein B mRNA editing in rat primary hepatocytes and McArdle cells.

Van Mater D, Sowden MP, Cianci J, Sparks JD, Sparks CE, Ballatori N, Smith HC

Biochemical and biophysical research communications.. 1998 November 18252 (2):334-9. Epub 1900 01 01.

Lipoprotein alterations in 10- and 20-week-old Zucker diabetic fatty rats: hyperinsulinemic versus insulinopenic hyperglycemia.

Sparks JD, Phung TL, Bolognino M, Cianci J, Khurana R, Peterson RG, Sowden MP, Corsetti JP, Sparks CE

Metabolism: clinical and experimental.. 1998 November 47 (11):1315-24. Epub 1900 01 01.

Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes.

Moyer MP, Tracy RP, Tracy PB, van't Veer C, Sparks CE, Mann KG

Arteriosclerosis, thrombosis, and vascular biology.. 1998 March 18 (3):458-65. Epub 1900 01 01.

Phosphoinositide 3-kinase activity is necessary for insulin-dependent inhibition of apolipoprotein B secretion by rat hepatocytes and localizes to the endoplasmic reticulum.

Phung TL, Roncone A, Jensen KL, Sparks CE, Sparks JD

The Journal of biological chemistry.. 1997 December 5272 (49):30693-702. Epub 1900 01 01.

Suppression of the protein tyrosine phosphatase LAR reduces apolipoprotein B secretion by McA-RH7777 rat hepatoma cells.

Phung TL, Mooney RA, Kulas DT, Sparks CE, Sparks JD

Biochemical and biophysical research communications.. 1997 August 18237 (2):367-71. Epub 1900 01 01.

Effects of fatty acids on apolipoprotein B secretion by McArdle RH-7777 rat hepatoma cells.

Sparks JD, Collins HL, Sabio I, Sowden MP, Smith HC, Cianci J, Sparks CE

Biochimica et biophysica acta.. 1997 July 121347 (1):51-61. Epub 1900 01 01.

Regulation of hepatic apolipoprotein B RNA editing in the genetically obese Zucker rat.

Phung TL, Sowden MP, Sparks JD, Sparks CE, Smith HC

Metabolism: clinical and experimental.. 1996 September 45 (9):1056-8. Epub 1900 01 01.

An auxiliary factor containing a 240-kDa protein complex is involved in apolipoprotein B RNA editing.

Schock D, Kuo SR, Steinburg MF, Bolognino M, Sparks JD, Sparks CE, Smith HC

Proceedings of the National Academy of Sciences of the United States of America.. 1996 February 693 (3):1097-102. Epub 1900 01 01.

Insulin-mediated inhibition of apolipoprotein B secretion requires an intracellular trafficking event and phosphatidylinositol 3-kinase activation: studies with brefeldin A and wortmannin in primary cultures of rat hepatocytes.

Sparks JD, Phung TL, Bolognino M, Sparks CE

The Biochemical journal.. 1996 January 15313 ( Pt 2) (Pt 2):567-74. Epub 1900 01 01.

Chromatographic method for isolation and quantification of apolipoproteins B-100 and B-48.

Sparks JD, Sparks CE

Methods in enzymology.. 1996 263 :104-20. Epub 1900 01 01.

Obese Zucker (fa/fa) rats are resistant to insulin's inhibitory effect on hepatic apo B secretion.

Sparks JD, Sparks CE

Biochemical and biophysical research communications.. 1994 November 30205 (1):417-22. Epub 1900 01 01.

Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion.

Sparks JD, Sparks CE

Biochimica et biophysica acta.. 1994 November 171215 (1-2):9-32. Epub 1900 01 01.

Liver regrowth and apolipoprotein B secretion by rat hepatocytes following partial hepatectomy.

Sparks JD, Corsetti JP, Sparks CE

Metabolism: clinical and experimental.. 1994 June 43 (6):681-90. Epub 1900 01 01.

Regulation of VLDL secretion in primary culture of rat hepatocytes: involvement of cAMP and cAMP-dependent protein kinases.

Björnsson OG, Sparks JD, Sparks CE, Gibbons GF

European journal of clinical investigation.. 1994 February 24 (2):137-48. Epub 1900 01 01.

Extract-specific heterogeneity in high-order complexes containing apolipoprotein B mRNA editing activity and RNA-binding proteins.

Harris SG, Sabio I, Mayer E, Steinberg MF, Backus JW, Sparks JD, Sparks CE, Smith HC

The Journal of biological chemistry.. 1993 April 5268 (10):7382-92. Epub 1900 01 01.

Cellular heterogeneity in binding and uptake of low-density lipoprotein in primary rat hepatocytes.

Corsetti JP, Sparks JD, Sikora B, Sparks CE

Hepatology : official journal of the American Association for the Study of Liver Diseases.. 1993 April 17 (4):645-50. Epub 1900 01 01.

Extracellular fatty acids are not utilized directly for the synthesis of very-low-density lipoprotein in primary cultures of rat hepatocytes.

Gibbons GF, Bartlett SM, Sparks CE, Sparks JD

The Biochemical journal.. 1992 November 1287 ( Pt 3) (Pt 3):749-53. Epub 1900 01 01.

Prostaglandins suppress VLDL secretion in primary rat hepatocyte cultures: relationships to hepatic calcium metabolism.

Björnsson OG, Sparks JD, Sparks CE, Gibbons GF

Journal of lipid research.. 1992 July 33 (7):1017-27. Epub 1900 01 01.

Immunolocalization, quantitation and cellular heterogeneity of apolipoprotein B in rat hepatocytes.

Corsetti JP, Way BA, Sparks CE, Sparks JD

Hepatology : official journal of the American Association for the Study of Liver Diseases.. 1992 June 15 (6):1117-24. Epub 1900 01 01.

Impaired hepatic apolipoprotein B and E translation in streptozotocin diabetic rats.

Sparks JD, Zolfaghari R, Sparks CE, Smith HC, Fisher EA

The Journal of clinical investigation.. 1992 May 89 (5):1418-30. Epub 1900 01 01.

The role of pancreatic hormones in the regulation of lipid storage, oxidation and secretion in primary cultures of rat hepatocytes. Short- and long-term effects.

Björnsson OG, Duerden JM, Bartlett SM, Sparks JD, Sparks CE, Gibbons GF

The Biochemical journal.. 1992 January 15281 ( Pt 2) (Pt 2):381-6. Epub 1900 01 01.

Effect of weight loss on serum lipoprotein(a) concentrations in an obese population.

Corsetti JP, Sterry JA, Sparks JD, Sparks CE, Weintraub M

Clinical chemistry.. 1991 July 37 (7):1191-5. Epub 1900 01 01.

The labeling of lipoproteins for studies of cellular binding with a fluorescent lipophilic dye.

Corsetti JP, Weidner CH, Cianci J, Sparks CE

Analytical biochemistry.. 1991 May 15195 (1):122-8. Epub 1900 01 01.

In vitro apolipoprotein B mRNA editing: identification of a 27S editing complex.

Smith HC, Kuo SR, Backus JW, Harris SG, Sparks CE, Sparks JD

Proceedings of the National Academy of Sciences of the United States of America.. 1991 February 1588 (4):1489-93. Epub 1900 01 01.

Quantitation of endogenous liver apolipoprotein B mRNA editing.

Backus JW, Eagleton MJ, Harris SG, Sparks CE, Sparks JD, Smith HC

Biochemical and biophysical research communications.. 1990 July 31170 (2):513-8. Epub 1900 01 01.

Insulin modulation of hepatic synthesis and secretion of apolipoprotein B by rat hepatocytes.

Sparks JD, Sparks CE

The Journal of biological chemistry.. 1990 May 25265 (15):8854-62. Epub 1900 01 01.

Blood cholesterol concentration: fingerstick plasma vs venous serum sampling.

Greenland P, Bowley NL, Meiklejohn B, Doane KL, Sparks CE

Clinical chemistry.. 1990 April 36 (4):628-30. Epub 1900 01 01.

Precision and accuracy of a portable blood analyzer system during cholesterol screening.

Greenland P, Bowley NL, French CA, Meiklejohn B, Gagliano S, Sparks CE

American journal of public health.. 1990 February 80 (2):181-4. Epub 1900 01 01.

Inhibition of apolipoprotein B net synthesis and secretion from cultured rat hepatocytes by the calcium-channel blocker diltiazem.

Kwong TC, Sparks JD, Pryce DJ, Cianci JF, Sparks CE

The Biochemical journal.. 1989 October 15263 (2):411-5. Epub 1900 01 01.

Insulin effects on apolipoprotein B production by normal, diabetic and treated-diabetic rat liver and cultured rat hepatocytes.

Sparks JD, Sparks CE, Miller LL

The Biochemical journal.. 1989 July 1261 (1):83-8. Epub 1900 01 01.

Insulin-mimetic effects of vanadate in primary cultures of rat hepatocytes.

Jackson TK, Salhanick AI, Sparks JD, Sparks CE, Bolognino M, Amatruda JM

Diabetes.. 1988 September 37 (9):1234-40. Epub 1900 01 01.

Effects of nonketotic streptozotocin diabetes on apolipoprotein B synthesis and secretion by primary cultures of rat hepatocytes.

Sparks JD, Sparks CE, Bolognino M, Roncone AM, Jackson TK, Amatruda JM

The Journal of clinical investigation.. 1988 July 82 (1):37-43. Epub 1900 01 01.

Secretion of high and low molecular weight phosphorylated apolipoprotein B by hepatocytes from control and diabetic rats. Phosphorylation of APO BH and APO BL.

Sparks JD, Sparks CE, Roncone AM, Amatruda JM

The Journal of biological chemistry.. 1988 April 15263 (11):5001-4. Epub 1900 01 01.

Clinical utility of Ektachem-determined bilirubin fractions for classifying adult inpatients.

Tetrault GA, Meiklejohn BA, Sparks CE

Clinical chemistry.. 1987 September 33 (9):1662-4. Epub 1900 01 01.

Insulin effects on apolipoprotein B lipoprotein synthesis and secretion by primary cultures of rat hepatocytes.

Sparks CE, Sparks JD, Bolognino M, Salhanick A, Strumph PS, Amatruda JM

Metabolism: clinical and experimental.. 1986 December 35 (12):1128-36. Epub 1900 01 01.

The production and utility of monoclonal antibodies to rat apolipoprotein B lipoproteins.

Sparks JD, Bolognino M, Trax PA, Sparks CE

Atherosclerosis.. 1986 September 61 (3):205-11. Epub 1900 01 01.

Hypercholesterolemia and aortic glycosaminoglycans of rabbits fed semi-purified diets containing sucrose and lactose.

Sparks JD, Sparks CE, Kritchevsky D

Atherosclerosis.. 1986 May 60 (2):183-96. Epub 1900 01 01.

Iodoprotein formation by rat mammary glands during pregnancy and early postpartum period.

Shah NM, Eskin BA, Krouse TB, Sparks CE

Proceedings of the Society for Experimental Biology and Medicine.. 1986 March 181 (3):443-9. Epub 1900 01 01.

Lipoprotein and protein binding of the calcium channel blocker diltiazem.

Kwong TC, Sparks JD, Sparks CE

Proceedings of the Society for Experimental Biology and Medicine.. 1985 February 178 (2):313-6. Epub 1900 01 01.

Apolipoprotein B and lipoprotein metabolism.

Sparks JD, Sparks CE

Advances in lipid research. 1985 21 :1-46. Epub 1900 01 01.

Catabolism of very low density lipoproteins in experimental nephrosis.

Garber DW, Gottlieb BA, Marsh JB, Sparks CE

The Journal of clinical investigation.. 1984 October 74 (4):1375-83. Epub 1900 01 01.

A comparison of the surface activities of rat plasma apolipoproteins C-II, C-III-0, C-III-3.

Krebs KE, Phillips MC, Sparks CE

Biochimica et biophysica acta.. 1983 May 16751 (3):470-3. Epub 1900 01 01.

Metabolism of two forms of apolipoprotein B of VLDL by rat liver.

Sparks CE, Rader DJ, Marsh JB

Journal of lipid research.. 1983 February 24 (2):156-66. Epub 1900 01 01.

The effect of fasting on the secretion of lipoproteins and two forms of apo B by perfused rat liver.

Marsh JB, Sparks CE

Proceedings of the Society for Experimental Biology and Medicine.. 1982 June 170 (2):178-81. Epub 1900 01 01.

Lipoprotein apolipoprotein synthesis by human hepatoma cells in culture.

Rash JM, Rothblat GH, Sparks CE

Biochimica et biophysica acta.. 1981 November 23666 (2):294-8. Epub 1900 01 01.

Hepatic and intestinal contribution of two forms of apolipoprotein B to plasma lipoprotein fractions in the rat.

Sparks CE, Hnatiuk O, Marsh JB

Canadian journal of biochemistry.. 1981 August 59 (8):693-9. Epub 1900 01 01.

Catabolism of the apolipoproteins of HDL in control and nephrotic rats.

Sparks CE, Tennenberg SD, Marsh JB

Biochimica et biophysica acta.. 1981 July 24665 (1):8-12. Epub 1900 01 01.

Catabolism of apoprotein A-1 of HDL in normal and nephrotic rats.

Sparks CE, Tennenberg SD, Marsh JB

Metabolism: clinical and experimental.. 1981 April 30 (4):354-8. Epub 1900 01 01.

Analysis of lipoprotein apoproteins by SDS-gel filtration column chromatography.

Sparks CE, Marsh JB

Journal of lipid research.. 1981 March 22 (3):514-8. Epub 1900 01 01.

Metabolic heterogeneity of apolipoprotein B in the rat.

Sparks CE, Marsh JB

Journal of lipid research.. 1981 March 22 (3):519-27. Epub 1900 01 01.

Hepatic secretion of lipoproteins in the rat and the effect of experimental nephrosis.

Marsh JB, Sparks CE

The Journal of clinical investigation.. 1979 November 64 (5):1229-37. Epub 1900 01 01.

Lipoproteins in experimental nephrosis: plasma levels and composition.

Marsh JB, Sparks CE

Metabolism: clinical and experimental.. 1979 October 28 (10):1040-5. Epub 1900 01 01.

Effect of residual enzymes on degradation of radioiodinated VLDL by collagenase-dispersed hepatocytes.

Capuzzi DM, Sparks CE, DeHoff JL

Biochemical and biophysical research communications.. 1979 September 2790 (2):587-95. Epub 1900 01 01.

Proteolysis of very low density lipoprotein in perfused lung.

Sparks CE, Dehoff JL, Capuzzi DM, Pietra G, Marsh JB

Biochimica et biophysica acta.. 1978 April 28529 (1):123-30. Epub 1900 01 01.

Metabolism of 125I-labeled lipoproteins by the isolated rat lung.

Pietra GG, Spagnoli LG, Capuzzi DM, Sparks CE, Fishman AP, Marsh JB

The Journal of cell biology.. 1976 July 70 (1):33-46. Epub 1900 01 01.

A STUDY OF HEMOGLOBIN DIFFERENTIATION IN RANA CATESBEIANA.

BAGLIONI C, SPARKS CE

Developmental biology.. 1963 December 8 :272-85. Epub 1900 01 01.